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Dysfunctions in mitochondrial dynamics and meta-
bolism are common pathological processes associ-
ated with Parkinson’s disease (PD). It was recently
shown that an inherited form of PD and dementia is
caused by mutations in the OPA1 gene, which en-
codes for a key player in mitochondrial fusion and
structure. iPSC-derived neural cells from these pa-
tients exhibited severe mitochondrial fragmentation,
respiration impairment, ATP deficits, and heightened
oxidative stress. Reconstitution of normal levels of
OPA1 in PD-derived neural cells normalized mito-
chondria morphology and function. OPA1-mutated
neuronal cultures showed reduced survival in vitro.
Intriguingly, selective inhibition of necroptosis effec-
tively rescued this survival deficit. Additionally,
dampening necroptosis in MPTP-treated mice pro-
tected from DA neuronal cell loss. This human
iPSC-based model captures both early pathological
events in OPA1mutant neural cells and the beneficial
effects of blocking necroptosis, highlighting this
cell death process as a potential therapeutic target
for PD.
INTRODUCTION
Degeneration of the dopaminergic (DA) neurons of the substantia
nigra is the main cause leading to the severe motor deficits
afflicting Parkinson’s disease (PD) patients. Over the past two
decades, several genes have been found to be mutated in rare
familial forms of PD, providing an opportunity to decipher the2066 Cell Reports 22, 2066–2079, February 20, 2018 ª 2018 The Aut
This is an open access article under the CC BY-NC-ND license (http://molecular causes underlying this disease (Abeliovich and Gitler,
2016; Hardy, 2010; Obeso et al., 2010). Importantly, the largest
group of PD-causative genes encodes for crucial modulators of
mitochondrial quality control and homeostasis (Giannoccaro
et al., 2017). A recent addition to this group is the dynamin-related
GTPase optic atrophy type 1 (OPA1), whose dominant heterozy-
gous mutations were identified in two families with chronic pro-
gressive external ophthalmoplegia (CPEO), parkinsonism, and
dementia (Carelli et al., 2015). OPA1 is a resident protein of
the innermitochondrial membrane and plays a key role in control-
ling both mitochondrial structure and dynamics (MacVicar and
Langer, 2016). OPA1 together with the mitofusins MFN1 and
MFN2 promote fusion of mitochondria, a process that is associ-
ated with increased respiratory efficiency (Cipolat et al., 2004). In
addition, OPA1 protein polymerization preserves cristaemorpho-
genesis, facilitating activity of the respiratory super-complexes
(Frezza et al., 2006). The absence of OPA1 severely destabilizes
the cristae structure and might lead to activation of the apoptotic
pathway (Frezza et al., 2006). However, fibroblasts from PD pa-
tients with OPA1 mutations presented a normal phenotype with
onlymildmitochondrial alterations (Carelli et al., 2015). Thus, it re-
mains unknown towhat extent theseOPA1mutations affectmito-
chondria activity in neural cells. Moreover, it would be relevant to
elucidate the molecular events that link primary mitochondrial
dysfunctions with the final downstream consequence as repre-
sented by the DA neuronal degeneration.
In neurodegenerative disease, the causative pathological
mechanisms are thought to stimulate a cascade of events lead-
ing to the activation of the programmed cell death (PCD) path-
ways responsible for irreversible neuronal cell demise (Levy
et al., 2009; Venderova and Park, 2012). In particular, solid
findings in cells and mice have shown that mitochondrial dys-
functions triggered by neurotoxins, such as 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) and rotenone, activate thehor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
apoptotic pathway (Vila and Przedborski, 2003). In fact, the
apoptotic Bcl-2 proteins Bax and Bak are activated downstream
to a defective respiratory complex I, leading to mitochondrial
outer membrane permeabilization, cytochrome c leakage, and
caspase cascade activation (Perier et al., 2007). However,
it remains less clear whether DA neuronal degeneration during
PD pathogenesis in humans is exclusively caused by apoptosis.
In fact, concurrent activation of both apoptosis and necrosis
have been described in human PD brain tissues (Levy et al.,
2009; Venderova and Park, 2012).
Thus, other non-apoptotic cell death modalities might play a
neglected role in DA neuronal loss. It is conceivable that multiple
adverse stimuli co-exist during PD pathogenesis, such as mito-
chondrial and lysosomal dysfunctions, protein misfolding,
inflammation, and bioenergetic alterations that can trigger mul-
tiple cell death pathways even in the same cell. In this regard,
the alternative PCD pathway known as necroptosis has
emerged to play a relevant role in triggering neuronal death in
neurodegenerative disorders (Conrad et al., 2016; Zhang
et al., 2017a). Necroptosis is a regulated process of necrosis
that is triggered by inflammatory signals and is dependent on
the RIPK1/3 kinases (Grootjans et al., 2017). In fact, when cas-
pase-8 is inactive, RIPK1 and RIPK3 are not cleaved but rather
associate forming the necrosome complex (Grootjans et al.,
2017). Activated RIPK3 phosphorylates and recruits MLKL,
which creates a supramolecular protein complex at the plasma
membrane leading to necroptosis execution by causing mem-
brane disruption (Conrad et al., 2016). Importantly, specific nec-
roptosis inhibitors, such as necrostatin-1 (Nec-1), have been
developed by targeting the kinase activity of RIPK1/3 (Degterev
et al., 2005). Recent research has revealed that in pathological
conditions with a strong inflammatory component, necroptosis
is a leading cause of neuronal cell death (Ito et al., 2016; Ofen-
geim et al., 2015; Re et al., 2014). In fact, in multiple sclerosis
(MS), tumor necrosis factor alpha (TNF-a) is upregulated and
leads to oligodendrocyte death by necroptosis, which can be
limited by Nec-1 (Ofengeim et al., 2015). Similarly, neuroinflam-
mation mediated by activated microglia mainly through the
TNF-a pathway has been shown to contribute to PD pathogen-
esis (Deleidi and Gasser, 2013). Remarkably, in GBA mutant
mice deficient for the lysosomal enzyme beta-glucocerebrosi-
dase as occurs in Gaucher’s lysosomal storage disease,
neuronal cell death mainly occurs via necroptosis (Vitner et al.,
2014). In fact, RIPK3 inactivation substantially improved the
clinical course of GBA mutant mice, rescuing neurological and
systemic deficits (Vitner et al., 2014). Importantly, heterozygous
mutations in GBA are the major risk factor for PD, causing lyso-
somal activity impairment and altered autophagy (Nalls et al.,
2013; Sidransky et al., 2009). Thus, these pathological pro-
cesses described in cellular and animal models of PD have
been previously associated with active necroptosis, however,
its contribution to this pathology has not yet been established.
In this study, we showed that PD-associated OPA1 mutations
in patient induced pluripotent stem cell (iPSC)-derived neural
cells cause severe mitochondrial dysfunctions, impaired oxida-
tive phosphorylation, and high oxidative stress levels, leading to
neuronal cell loss. Importantly, necroptosis inhibition rescued
the neuronal differentiation potential of these cells and waseffective in protecting nigral DA neurons in mice treated with
the MPTP neurotoxin.
RESULTS
PD-OPA1 Mutant iPSC-Derived NPCs Exhibit
Morphological and Functional Mitochondrial Alterations
To investigate the pathological bases of the OPA1 mutations
leading to PD, skin fibroblasts were obtained from two individ-
uals manifesting PD symptoms, one for each family, and reprog-
rammed into iPSCs with a non-integrating system based on
Sendai viruses expressing the Yamanaka genes (CytoTune-
iPS). For the subsequent functional studies, iPSC lines were
initially selected based on the correct colony morphology,
expression of crucial pluripotency genes, and silencing of fibro-
blast-specific genes (Figures S1A–S1AO). Then, iPSCs were
assessed for multi-lineage cell differentiation competence as
validated by the generation in vitro of somatic cells for the three
germinal layers (data not shown). Moreover, Sanger sequencing
confirmed the presence of the p.G488R or the p.A495V disease
mutation, and iPSCs maintained a normal euploid karyotype
over several passages in vitro (Figures S1AP and S1AQ). We
then selected iPSC lines from age-matched normal donors that
passed the equivalent quality control procedures (Figure S1). It
was recently reported that iPSC lines might carry a heavy load
of homoplasmic or heteroplasmic mtDNA mutations, reflecting
the mtDNA state present in the single fibroblast from which
each cell line was derived (Kang et al., 2016; Lorenz et al.,
2017; Perales Clemente et al., 2016). This unfavorable event is
even more pronounced in iPSCs derived from the fibroblasts
of elderly people that present a significantly higher incidence
of mtDNA defects in the overall cell population (Kang et al.,
2016). Considering these results, functional studies to profile
the mitochondrial activity in patient iPSCs need to be performed
excluding confounding effects of the disease-independent
harmful mtDNA mutations. To this end, mtDNA from iPSC lines
derived from both OPA1-mutant PD patients (PD-OPA1 iPSCs)
and normal donors was fully sequenced and analyzed. Among
the six different iPSC lines, G488R #34 and G488R #37 carried
a homoplastic disruptive mutation in the ND5 gene and were
therefore discarded (data not shown). Conversely, PD-OPA1
iPSC lines G488R #12, G488R #22, and A495V #72 and normal
donor (ND) #37 and ND #68 did present few synonymous
mutations without any predictable functional significance (Fig-
ure S2A). Hence, we focused on these five lines for the following
studies. Immunoblotting analysis showed that OPA1 protein
levels were reduced in all the PD-OPA1 iPSC lines, suggesting
that the missense mutations lead to protein instability and
increased protein degradation (Figures S2B and S2C). In support
of this, levels of OPA1 gene transcripts were comparable among
all the lines, suggesting that the mutations operate through a
post-transcriptional mechanism (Figure S2E).
To rescue the phenotypic defects directly caused by the OPA1
gene mutations, we integrated by lentiviral transduction the
wild-type OPA1 isoform 1 into each of the three PD-OPA1 iPSC
lines. Then, for each PD-OPA1 iPSC line, one OPA1-comple-
mented cell line was selected with levels of total OPA1 protein
comparable to those present in ND cells (Figures S2B andCell Reports 22, 2066–2079, February 20, 2018 2067
Figure 1. Mitochondrial Network Mor-
phology of PD-OPA1, Normal Donor (ND),
and OPA1-Complemented NPCs
(A–G) Representative images of mitochondrial
morphology stained with TOMM20 (green) in
PD-OPA1 (B–D), ND (A), and OPA1-com-
plemented (E–G) NPCs.
(H) Quantification of mitochondrial morphology
confirming the fragmented morphology in PD-
OPA1 compared with ND and OPA1-com-
plemented NPCs.
(I and J) Transmission electron microscopy (TEM)
images (I) showing the mitochondria-altered
morphological aspect. The mitochondrial size
was calculated by measuring the perpendicular
axis with respect to the larger diameter for all
the mitochondria (200 mitochondria in total) and
relative quantifications (J).
Data are mean ± SEM, n = 3 independent exper-
iments. **p < 0.01, ***p < 0.001 for ND NPCs and
p < 0.01, p < 0.001 for OPA1-complemented
NPCs. Statistical analysis was performed using
one-way ANOVA followed by Tukey post-test.
Scale bars, 100 mm (A–G), 500 nm (I).S2D). Both PD-OPA1 and ND iPSC lines showed a comparable
growth ratewith long-term, stablemaintenance of the undifferen-
tiated state. This was expected considering that iPSC meta-
bolism and bioenergetics mostly rely on aerobic glycolysis
(Folmes et al., 2011). Conversely, iPSC-differentiated somatic
cell lineages, as in particular neuronal cells, requires mitochon-
drial biogenesis andmaturation of efficient oxidative energy gen-
eration for metabolic sustenance (Lorenz et al., 2017). Hence,
we directed the differentiation of iPSCs into neural progenitor
cells (NPCs) by generating neural rosettes through a sequential
exposure to SB431542 and Noggin to select a population of
Nestin/Pax6 double-positive cells growing in a basal-free me-
diumwith basic fibroblast growth factor (bFGF) and B27/N2 sup-
plements (Figure S3). Once we obtained highly homogeneous
NPCscomparablewith respect to cell growth andnumber of pas-
sages in vitro (Figure S3), we carried out a detailedmorphological
assessment of their mitochondrial component. Interestingly, im-
munostaining for the protein of the external mitochondrial mem-
brane TOMM20 showed a filamentous mitochondrial network in2068 Cell Reports 22, 2066–2079, February 20, 2018ND NPCs, which was significantly frag-
mented in the PD-OPA1 NPCs (Figures
1A–1Dand1H). This aberrantmorphology
was normalized in the OPA1-comple-
mented patient NPCs, indicating that
this defect was directly caused by OPA1
gene alterations (Figures 1E–1H). On the
same line, quantitative measurement of
transmission electron microscopy im-
ages confirmed that OPA1-mutant mito-
chondria were reduced in length with a
tendency to present a round-shaped
morphology (Figures 1I and 1J).
Given the significantly alteredmitochon-
drial morphology in PD-OPA1 NPCs, wethoroughly evaluated mitochondrial functionality using several
readouts. Initially, total mitochondrial content was quantified by
Mitotracker-green staining, which localizes to the mitochondria
irrespective of a charged mitochondrial membrane potential both
in live staining and flow cytometry. Interestingly, PD-OPA1 NPCs
showed a significant loss in total mitochondrial content (Figures
2A–2L and 2P). In concurrent independent assays, mitochondrial
membrane potential was assessed with orange CMTMRos fluo-
rescent dye, whose accumulation in the mitochondria is corre-
lated to the membrane potential. This analysis revealed that a
significant fraction of the PD-OPA1 NPC mitochondria had a
reduced membrane potential (Figures 2A–2L and 2Q). Remark-
ably, both the total mass and membrane potential of mitochon-
dria were robustly complemented in the OPA1-rescued mutant
cell lines (Figures 2M–2O, 2R, and 2S). Overall, these results
revealed that the PD-OPA1 NPCs have a global altered mito-
chondrial network, with loss of the overall mass and a significant
fraction of dysfunctional organelles. Given these results, we
sought to determine if these alterations might affect the overall
Figure 2. OPA1 Mutant NPCs Show Reduced and Dysfunctional Mitochondrial Content
(A–O) Representative images of MitoTracker Green and Orange CMTMRos in PD-OPA1 (D–L), ND (A–C), and OPA1-complemented (M–O) NPCs.
(P and Q) Quantification of fluorescence intensity of Mitotracker Green (P) and Orange CMTMRos (Q) by flow cytometetry highlights a reduction in number and
functionality of mitochondria in PD-OPA1 NPCs.
(R and S) The introduction of the wild-type OPA1 gene re-establishes the normal content (R) and activity (S) of mitochondria in PD-OPA1 NPCs.
Data are mean ± SEM of n = 3 independent experiments. *p < 0.05. Statistical analysis was performed using one-way ANOVA followed by Tukey post-test. Scale
bars, 100 mm.
Cell Reports 22, 2066–2079, February 20, 2018 2069
Figure 3. Activity and Mitochondrial Mem-
brane Potential Are Affected in PD-OPA1
NPCs
(A) OCR measurements of control and PD-OPA1
NPCs analyzed individually. OCR is normalized to
cell number. OCR is measured in basal conditions
and after oligomycin, FCCP, and rotenone addi-
tion. OCR results lower in all tested conditions in
PD-OPA1 compared with ND NPCs.
(B and C) Quantification of total mitochondrial ATP
(B) and complex I-driven ATP (in the presence of
5 mM pyruvate plus 5 mM malate) (C). Concen-
tration in the NPC medium. PD-OPA1 compared
with ND NPCs produce less ATP and more lactate
than controls.
(D) Effect of oligomycin (O) on mitochondrial
membrane potential. Control and OPA1-mutant
NPCs are loaded with TMRM as described in the
Experimental Procedures. F, FFCP.
(E) Quantification of L-lactate concentration in the
NPC medium.
Data are mean ± SEM; n = 3 independent experi-
ments. *p < 0.05, **p < 0.01, ***p < 0.001. Statis-
tical analysis was performed by Student’s t test (A)
or one-way ANOVA followed by Tukey post-test
(B and C).bioenergetic profile of these cells. Initially,we investigated respira-
tory activity as a critical parameter of mitochondrial function.
Oxygen consumption in NPCs was determined by microscale
oxygraphy in basal conditions or in response to the ATP synthase
inhibitor oligomycin, the proton ionophore FCCP, and the mito-
chondrial complex I inhibitor rotenone. The oxygen consumption
rate (OCR) was significantly reduced in PD-OPA1 NPCs in all the
conditions tested (Figure 3A). Accordingly, direct measurements
of totalATPproduction inpermeabilizedcells revealedasignificant
reduction in ATP levels in the PD-OPA1 compared with control
NPCs (Figure 3B), confirming a dysfunctional oxidative meta-
bolism and mitochondrial uncoupling. Importantly, the ATP levels
remainedseverelyaffected inPD-OPA1NPCsalso in thepresence
of pyruvate and malate, which stimulate complex I ATP produc-
tion. These findings indicate that PD-OPA1NPCs have a defective
respiratory complex I, which leads to a robust loss of intracellular
ATP content (Figure 3C).
We then evaluated the mitochondrial membrane potential
(MMP) as determined by loading with TMRM, a fluorescent dye
that accumulates in polarized mitochondria and is released
when MMP decreases. MMP maintained in the presence of the
ATP-synthase inhibitor oligomycin (Figure 3D) was drastically
reduced in PD-OPA1 NPCs (Figure 3D). If mitochondria-depen-
dent energetics is insufficient, the aerobic glycolytic pathway2070 Cell Reports 22, 2066–2079, February 20, 2018might be upregulated to cope with the
metabolic needs. According to this sce-
nario, medium from PD-OPA1 NPCs pre-
sented increased levels of lactate, the
final metabolic product of glycolysis, sug-
gesting a partial shift in themetabolic pro-
gram (Figure 3E). Accordingly, the hexoki-
nase-2 (HK2) gene, encoding for thekinase catalyzing the rate-limiting step of glucose metabolism
was found upregulated in PD-OPA1 NPCs (Figure S4).
Heightened Oxidative Stress and Lysosomal Impairment
in PD-OPA1 NPCs
An adverse effect of impaired respiration is the increase of
radical oxygen species (ROS) generation. Thus, we monitored
the intracellular oxidants using the fluorescent ROS-sensitive
20-70-dichlorodihydrofluorescein diacetate (DCFDA) on NPCs
in basal conditions. Noticeably, ROS levels were strongly
enhanced in the PD-OPA1 compared with the ND NPCs (Figures
4A–4D and 4P).We then evaluatedmembrane oxidants using the
lipophilic dye BODIPY-C11, whose signal vanished after interac-
tion with peroxyl radicals. In accordance with DFCDA results, the
BODIPY-C11 fluorescence was strongly diminished in PD-OPA1
NPCs indicating high levels of membrane oxidants in these cells
(Figures 4F–4I and 4Q). As expected, OPA1 gene reintroduction
was sufficient to normalize both ROS and oxidized lipid levels in
PD-OPA1 NPCs (Figures 4E, 4J, 4S, and 4T). In addition, we
measured the reduced form of glutathione using the Thioltracker
violet probe. In line with the heightened ROS levels, significantly
lower levels of reduced glutathione were detected in PD-OPA1
NPCs that were recovered after OPA1 gene reintroduction
(Figures 4K–4O, 4R, and 4U). High intracellular ROS promotes
Figure 4. High Oxidative Stress Level in PD-OPA1 NPCs
(A–O) Representative images of NPCs stained with ROS-sensitive fluorescent probe DCFDA (A–E), BODIPY Lipid Probe (F–J), and ThiolTracker Violet (K–O).
(P–R) Quantification of DCFDA (P), BODIPY (Q), and ThiolTracker Violet (R) fluorescence reveal the heightened oxidative state in PD-OPA1 NPCs.
(S–U) OPA1 gene complementation is effective in significantly reducing the heightened oxidative state (S), lipid oxidation (T), and oxidized glutathione (U).
(V and W) OxyBlot assay (V) and quantification (W) of carbonylated protein levels confirming the altered oxidative condition of PD-OPA1 NPCs. Quantification of
carbonylated protein signal was performed after normalization to the housekeeping protein actin.
Data are mean ± SEM; n = 3–4 independent experiments. *p < 0.05, ***p < 0.001 for ND NPCs and p < 0.05, p < 0.001 for OPA1-complemented NPCs.
Statistical analysis was performed using one-way ANOVA followed by Tukey post-test. Scale bars, 100 mm.
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protein carbonylation that can be evaluated by OxyBlot. The
results confirmed that PD-OPA1 NPCs showed increased car-
bonylated protein levels compared with control NPCs (Figures
4Vand 4W). According to these results, RNA sequencing
(RNA-seq) analysis showed a number of genes belonging to
ROS-dependent molecular pathways whose expression was
altered in PD-OPA1 NPCs (Figure S4). In fact, qPCR assays
confirmed that expression levels of the SOD1 and SOD2 dismu-
tases, SESTRIN3, and NRF2 and its target gene GPX1 were
robustly increased in PD-OPA1 NPCs (Figure S4). Importantly,
OPA1 complementation was sufficient to significantly reduce
oxidized protein levels in all of the three PD-OPA1 NPC lines (Fig-
ures 4V and 4W).
High intracellular ROS levels might seriously compromise over
time the functionality of cellular organelles. The lysosomal total
content was not evidently changed in PD-OPA1 compared
with ND NPCs as assessed by LAMP1 immunostaining (Figures
5A–5D, 5I, 5K, and 5N). However, the LysoTracker fluorescent
probe, which stains exclusively functional lysosomes with an
acidic content, revealed a reduced number of active lysosomes
in PD-OPA1 NPCs (Figures 5E–5H and 5J). A lysosomal impair-
ment in these cells was also independently suggested by detect-
ing an increasing amount of the total P62 protein, whose turnover
is regulated exclusively by lysosomal-dependent degradation
(Figures 5L and 5O). On the same line, PD-OPA1 NPCs showed
a reduced amount of the mature form of cathepsin D, a lyso-
somal enzyme involved in alpha-synuclein degradation (Figures
5M and 5P) (Bae et al., 2015). Accordingly, other lysosomal
genes and the master regulator TFEB were to some extent
downregulated, further indicating an alteration in the lysosome-
dependent molecular pathway (Figure S4).
Reduced Neuronal Differentiation Potential of PD-OPA1
NPCs and Rescue by Small Molecules
We next examined patient and control NPCs for their potential
to generate post-mitotic neurons and, in particular, DA neurons.
Concomitant CHIR99021 treatment with sonic hedgehog (SHH)
signaling activation, followed by a change in Neurobasal medium
supplemented with Forskolin, ascorbic acid, and neurotrophins,
induced complete NPC differentiation into neurons and astro-
cytes. In particular, at twomonths from initial NPC differentiation,
control neuronal cultures contained 73% ± 6% MAP2+ neurons,
of which 42% ± 6% expressed TH+ (triplicates for five indepen-
dent experiments) (Figures 6A 6Q, and 6R). Of note, despite
TH+ neurons not displaying an evident regional identity, they ex-
press the crucial markers of the DA neuronal sub-type and were
functional as assessed by their ability to produce and release
dopamine (Figures S5A–S5F). Strikingly, neuronal cultures from
all three PD-OPA1 NPCs showed a consistent decrease in the
MAP2+ neuronal population (62%± 5%)with an evenmore signif-
icant loss of TH+ neurons (18%± 7%) (triplicates for four indepen-
dent experiments) (Figures 6E–6P, 6Q, and 6R). This neuronal
deficiency was not associated with a complementary increase
in the astrocyte number, indicating that this loss is not caused
by an aberrant neural lineage commitment of the PD-OPA1
NPCs (data not shown). Quantitative analysis of one-month-old
neuronal cultures revealed already a decreased neuronal content
in the PD-OPA1 group, suggesting a premature impairment in2072 Cell Reports 22, 2066–2079, February 20, 2018neuronal survival (data not shown). Remarkably, OPA1 reconsti-
tution rescued the neuronal survival impairment in all three
PD-OPA1 mutant neuronal cultures (Figures S5G–S5L). Given
the serious dysfunctions previously described in the PD-OPA1
NPCs, we wondered whether these alterations were maintained
in the post-mitotic neurons. In fact, DCFDA fluorescent staining
confirmed that intracellular ROS levels were higher in the
PD-OPA1 compared with control neurons (Figure S6). Thus, the
functional alterations described in the PD-OPA1 NPCs are likely
the cause of the underlying neuronal differentiation impairment.
In addition, we analyzed the mtDNA copy number in both NPCs
and their differentiated neuronal progeny. Noticeably, although
mtDNA content was comparable in NPCs independently from
their genotype, OPA1 mutant presented a significantly higher
mtDNA copy number compared with ND neurons (Figure S7).
This increasedmtDNA biogenesis in OPA1mutant neuronsmight
be a compensatory response to the severe mitochondrial func-
tional deficits affecting these cells.
We then attempted to rescue this neuronal loss using candidate
small molecules. In particular, we initially selected obvious candi-
dates, such as N-acetylcysteine (NAC), a strong antioxidant
acting by replenishing glutathione levels and Z-VAD, a strong
cell-permeable apoptotic inhibitor with a pan-caspase blocking
activity. When either NAC or Z-VAD where added throughout
thedifferentiationperiod, theyexerteda robusteffect inpromoting
survival of the general neuronal population and the TH+ neurons
derived from the PD-OPA1 NPCs (Figures 6B–6O, 6Q, and 6R).
However, Z-VAD was, in general, less potent than NAC in pro-
tecting from neuronal cell loss. Although apoptosis is the most
common process investigated during neuronal cell loss in neuro-
degenerative diseases, the alternative cell death pathway of nec-
roptosis has recently been found to contribute to theseprocesses
as well (Conrad et al., 2016; Zhang et al., 2017a). Noticeably, the
immunoblotting analysis revealed a robust increase in RIPK1,
RIPK3, and MLKL protein levels in PD patients compared with
ND-derived post-mortem nigral tissue (Figure S8A). Likewise,
neuronal cultures from all three PD-OPA1 mutant cell lines ex-
hibited heightened RIPK1, RIPK3, and MLKL protein levels (Fig-
ure S8B). Thus, we differentiated PD-OPA1NPCs in the presence
of Nec-1s, a specific and potent necroptosis inhibitor (Takahashi
et al., 2012). Strikingly, Nec-1s showed a strong effect in promot-
ing PD-OPA1 neuronal survival comparable to that obtained with
Z-VAD (Figures 6D–6P, 6Q, and 6R).
In contrast, treatment with thesemolecules for only a few days
at late stages of differentiation did not obtain any functional
rescue, indicating that extended treatment is necessary for their
beneficial effects (data not shown).
Pharmacological Inhibition of Necroptosis Protects
from MPTP-Induced DA Neuronal Cell Loss and
Attenuates Oxidative Stress
Considering the beneficial effects triggered by necroptosis
inhibition in PD-OPA1 neurons, we next thought to inhibit this
pathway in vivo in a well-established PD mouse model based
on sub-acute MPTP intoxication (Sedelis et al., 2001). MPTP is
oxidized to the neurotoxin MPP+, which is specifically trans-
ported by DAT into the DA neuronal terminals and soma where
it interferes with mitochondrial complex I activity leading to
Figure 5. Lysosomal Activity Impairment in PD-OPA1 NPCs
(A–H) Representative images of NPCs stained with LAMP1 (A–D) and LysoTracker Red (E–H).
(I and J) Quantification of LAMP1 (I) and LysoTracker (J) stainings show a loss of lysosomal acidic pH in PD-OPA1 NPCs. Quantification was performed by
analyzing the number of dots normalized on the cell surfaces.
(K and N) Immunoblot analysis (K) and relative quantification (N) for LAMP1 indicates a comparable lysosomal content in PD-OPA1 and ND NPCs.
(L and O) Immunoblot analysis (L) and quantification of intensity (O) of p62 protein levels after normalization to the housekeeping protein.
(M and P) Immunoblot analysis (M) and relative quantification (P) for cathepsin D (CTSD) reveals a reduction of intensity of CTSD in PD-OPA1 NPCs.
Data aremean ±SEM, n = 3–4 independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001. Statistical analysis was performed using one-way ANOVA followed by
Tukey post-test. Scale bars, 100 mm (A–D), 50 mm (E–H).severe deficits in ATP formation and an increase in ROS produc-
tion that in turn, cause an energy crisis and oxidative stress (Vila
and Przedborski, 2003). Therefore, MPTP-dependent neuronal
cell loss recapitulates the cardinal defects on mitochondrial
complex I described in the PD-OPA1 neuronal cells and, there-fore, represents a suitable in vivomodel for evaluating the neuro-
protective potential of necroptosis inhibition.
Mice were injected daily for five consecutive days with MPTP
(20 mg/kg; intraperitoneally [i.p.]) and concomitantly injected
with 1 mg of Nec-1 for 21 days. Due to the poor BBB penetrationCell Reports 22, 2066–2079, February 20, 2018 2073
Figure 6. PD-OPA1 NPCs Have a Reduced
Neuronal Differentiation Potential
(A–P) TH (green) and MAP2 (red) immunofluores-
cence staining for PD-OPA1 and ND NPC-derived
neurons in the basal condition (A, E, I, and M) or
treated with NAC (B, F, J, and N), Z-VAD (C, G, K,
and O), or Nec-1s (D, H, L, and P).
(Q and R) PD-OPA1 NPCs generated a reduced
number of viable neurons compared with ND
NPCs after two months in culture. All the treat-
ments increased the number ofMap2+ (Q) and TH+
(R) cells, showing a protective effect on the NPC
differentiation potential. However, Z-VAD is less
efficient than NAC and Nec-1s in protecting from
DA neuronal death.
Data expressed as mean ± SEM, n = 4 in-
dependent experiments. *p < 0.05, **p < 0.01
***p < 0.001. Statistical analysis is performed using
two-way ANOVA followed by Bonferroni post-test.
Scale bars, 100 mm.of this compound, mice were previously implanted with a can-
nula for chronic intra-cerebral ventricle (ICV) injections. At
day 21, mice were sacrificed and brains processed for biochem-
ical and histological evaluation. TH immunolabeling in DA striatal
fiber density was quantified by optical density. The neurotoxic
effect caused by MPTP led to a 50% reduction of TH+ fibers
compared with the saline-treated group (Figures 7A–7D). In
contrast, Nec-1 treatment led to a 34% fiber density decline
in MPTP-treated mice, accounting for about 15% of recovery
(Figures 7A–7D). To determine the effective loss of DA neurons,
stereological counting was performed on the whole TH-stained
nigral tissue. MPTP treatment caused a 60% loss of DA nigral
neurons, which was reduced to 27%with the Nec-1 co-adminis-
tration (Figures 7E–7H). These results indicate that Nec-1 by ICV
delivery has a substantial effect in reducing MPTP-induced DA
neuronal degeneration. To establish a less invasive and more
feasible treatment, we switched to a derivative of Nec-1, known
as Nec-1s (7-ClO-Nec-1), which has superior stability, reduced
off-target effects, and is capable of crossing the blood-brain bar-
rier (Takahashi et al., 2012). The i.p. Nec-1s administration ex-
erted significant neuroprotection by reducing the loss of striatal2074 Cell Reports 22, 2066–2079, February 20, 2018DA fiber from 42% to 29% and the num-
ber of nigral DA neurons from 47% to
21% compared with MPTP treatment
alone (Figures 7I–7P). Thus, peripheral
delivery of Nec-1s achieved substantial
DA neuronal protection from MPTP
comparable to the effects obtained
with the Nec-1 ICV injections. Next, we
wondered whether Nec-1s neuroprotec-
tion was achieved by modulating any of
the cellular dysfunctions caused by the
MPTP-dependent mitochondrial impair-
ment. Specifically, as a reliable indicator
of intracellular oxidative stress levels,
we performed immunohistochemistry for
4-hydroxynonenal (4-HNE), an aldehydicproduct of lipid peroxidation. Interestingly, Nec-1s treatment
significantly reduced the strong 4-HNE immunofluorescence
signal in TH+-nigral DA neurons caused by theMPTP intoxication
(Figure S9). Altogether, these data demonstrate that pharma-
cological inhibition of necroptosis is effective in reducing DA
neuronal loss caused by MPTP-dependent mitochondrial
intoxication.
DISCUSSION
Herein, we showed that iPSC-based disease modeling un-
masked a full spectrum of mitochondrial dysfunctions in neural
cells harboring two different OPA1 mutations associated with
parkinsonism and nigrostriatal degeneration. iPSC-derived
neural cells showed a compromised mitochondrial network in
basal conditions with impaired oxidative metabolism and
heightened oxidative stress. Importantly, most of these deficits
were not readily detectable in fibroblasts from patients under
basal conditions, indicating that the iPSC modeling is pivotal
for the exploitation of the mechanisms leading to neurodegen-
eration (Carelli et al., 2015). In our analysis, OPA1-A495V
Figure 7. Inhibition of Necroptosis Attenu-
ates Nigrostriatal Degeneration Induced by
MPTP Treatment
(A–C) Representative pictures of TH+ fibers in the
striatum of animals used for Nec-1 treatment.
(I–K) Representative pictures of TH+ fibers in the
striatum of animals used for Nec-1s treatment.
(D and L) Quantification of TH+ fiber density
calculated as the mean of the level of greys (8-bit)
showed a reduction in MPTP-treated mice
compared with saline-injected mice and a partial
restoration in both Nec-1 (D) and Nec-1s (L)
groups.
(E–G) Representative pictures of TH+ neurons in
SN animals used for Nec-1 treatment.
(M–O) Representative pictures of TH+ neurons in
SN animals used for Nec-1s treatment.
(H and P) Stereological quantification highlights a
decrease in the total number of TH+ neurons in
animals receiving MPTP. The neuronal loss was
prevented by Nec-1 (H) and Nec-1s (P) treatment.
Values are means ± SEM; n = 5–8 animals.
*p < 0.05, **p < 0.01, ***p < 0.001. Statistical
analysis was performed using one-way ANOVA
followed by Tukey post-test. Scale bar, 2mm (A–C
and J–L), 400 mm (E–G, and M–O).neural cells exhibited, in general, more severe alterations
compared with those detected in OPA1-G488R analogous
cells. Interestingly, this difference matches the clinical diver-
sity at the time of the last clinical assessment between the
two patients carrying either the A495V or G488R mutation. In
fact, the former displayed a fully symptomatic parkinsonism
with bradykinesia, rigidity, and postural tremor (individual
III-1 in Family 2), whereas the latter had only a partial nigros-
triatal degeneration based on DAT-scan imaging but did not
yet have the full-blown motor symptoms of parkinsonism (indi-
vidual III-11 in Family 1) (Carelli et al., 2015).
OPA1 mutations are a common cause of pure dominant optic
atrophy (DOA) which, however, might be associated with addi-
tional debilitating neurological manifestations, including CPEO,
sensorineural deafness, ataxia, myopathy, and polyneuropathy,
referred to as DOA ‘‘plus’’ (Amati-Bonneau et al., 2008; Yu-Wai-
Man et al., 2010). Only recently were parkinsonism and dementia
shown to be associated with two novel OPA1 mutations (Carelli
et al., 2015). Our work provides a detailed analysis of the
mitochondrial and metabolic deficits caused by these peculiar
OPA1 mutations, showing that these alterations can lead to
neuronal survival defects in iPSC-derived neural cells. Future
studies are needed to understand whether only these mutations
can trigger an irreversible neurodegenerative process. Previous
studies have shown that some of the defects described herein
in the iPSC derivatives are consistent with the alterations
described in other cell types from DOA and DOA-plus patientsCell Repo(Chevrollier et al., 2008; Zanna et al.,
2008). For instance, PD-OPA1 NPCs
shared with DOA-plus primary cells a
recurrent and prevalent impairment of
ATP synthesis when driven by complex Isubstrates (Carelli et al., 2015; Zanna et al., 2008), which has
been subsequently proposed to be related to poor super-
complex formation determined by altered cristae morphology
(Cogliati et al., 2013). Overall, these findings suggest that
DOA-plus patients could be at seriously increased risk of devel-
oping parkinsonism during disease progression at an elderly
age. Thus, these results call for longitudinal clinical evaluation
of these patients over an extended period of time to ascertain
this important eventuality. Additionally, generation of iPSCs
from DOA-plus patients and the characterization of their differ-
entiated neuronal cells, as carried out herein, might provide
important indications as to whether this is a likely possibility.
The DOA syndromic form is also associated with the increased
accumulation and clonal expansion of multiple mtDNA deletions
in post-mitotic tissues, such as skeletal muscle, resulting in the
emergence of cytochrome c oxidase-negative and ragged-red
fibers (Amati-Bonneau et al., 2008; Yu-Wai-Man et al., 2010).
Furthermore, reduced or abolished expression of OPA1 is also
associated with mtDNA depletion (Del Dotto et al., 2017). The
potential combination to various degrees of accumulation and
clonal expansion of mtDNA deletions with reduced copy number
might be a strong determinant of the multi-organ pathology
that develops in an age-related fashion, ultimately including
DA neurons and related parkinsonism (Carelli et al., 2015; Yu-
Wai-Man et al., 2010). iPSC-derived neurons did not present
loss or deletions in mtDNA, while they exhibited a significant
increase in mtDNA copy number. This is in agreement with therts 22, 2066–2079, February 20, 2018 2075
compensatory activation of mitochondrial biogenesis and
increased mtDNA copy number documented in both the blood
cells and skeletal muscle of patients with Leber’s hereditary op-
tic neuropathy (Giordano et al., 2014), a complex I disorder, and
OPA1-related DOA (Iommarini et al., 2012). In fact, disturbed
mtDNA maintenance appears to be only a late age-related event
during OPA1 disease progression (Amati-Bonneau et al., 2008).
This indicates that OPA1 pathogenetic mechanisms primarily
impact onmitochondrial dynamics andmitochondrial respiratory
complex structural organization and function and only subse-
quently lead to mtDNA defects. Thus, our observation of
increased mtDNA copy number in PD-OPA1 iPSC-derived neu-
rons most probably reflects the initial phase of the disease when
mitobiogenesis is activated to cope with the defective mitochon-
drial functions caused by OPA1 mutations. This is consistent
with the young age of the iPSC-derived neurons in vitro that
poses limitations for modeling age-related neurodegenerative
processes. However, our results suggest that substantial mito-
chondrial deficits have a strong impact on neuronal survival
in vitro, where metabolic constrains might limit their resilience
to these insults. A similar spectrum of neurological symptoms,
including severe nigrostriatal degeneration associated with mul-
tiple mtDNA deletions, can be caused by mutations in the nu-
clear genes POLG and C10orf2 (Fratter et al., 2010; Horvath
et al., 2006). However, in these cases, POLG and C10orf2
encode for mitochondrial proteins with a key role in mtDNA
replication, suggesting that impaired mtDNA maintenance is
the primary cause of these diseases (Young and Copeland,
2016). Thus, it remains to be understood whether mtDNA integ-
rity loss in OPA1-dependent parkinsonism is a primary and
necessary trigger for neuronal cell loss. Nonetheless, our data
indicate that OPA1-dependent dysfunctions in mitochondrial
metabolism and dynamics in iPSC-derived neural cells are suffi-
cient to elicit some neuronal cell loss without compromising
mtDNA integrity.
Intriguingly, our findings indicate for the first time that necrop-
tosis is activated on neuronal cell loss caused by mitochondrial
dysfunctions both in vitro and in vivo. In particular, nigral DA neu-
rons were significantly protected from the MPTP toxic effects
with the peripheral administration of Nec-1s. Necroptotic cell
death is triggered by diverse inflammatory stimuli through stim-
ulation of the TNF family death domain receptor (Conrad et al.,
2016). In fact, it was shown that in neurodegenerative diseases
with an overt inflammatory component, such as MS and amyo-
trophic lateral sclerosis (ALS), there is strong activation of this
non-apoptotic cell death pathway (Ito et al., 2016; Ofengeim
et al., 2015; Re et al., 2014). Mounting evidence indicates a
strong inflammatory component during PD progression, as re-
vealed by a local increase in glial reaction and pro-inflammatory
cytokine release (Deleidi and Gasser, 2013). Similarly, MPTP
leads to microglial activation and local neuroinflammation both
in humans and mice (Hirsch et al., 2005; Martin et al., 2016). In
addition, it has been recently shown that RIPK1 is a sensor for
ROS, which can stimulate RIPK1 auto-phosphorylation and acti-
vate necroptosis (Zhang et al., 2017b). Thus, both inflammation
and oxidative stress might initiate the necroptotic pathway
during PD disease progression. We described that PD-OPA1
iPSC-derived neural cells accumulate high levels of intracellular2076 Cell Reports 22, 2066–2079, February 20, 2018ROS, and presumably, this might contribute to the activation of
necroptosis in our in vitro culture system.
Previous studies have convincingly elucidated the molecular
mechanisms that associate MPTP-related mitochondrial dys-
functions with apoptotic neuronal cell death (Perier et al.,
2007). However, different levels of protection from MPTP-
induced cell death were achieved depending on which apoptotic
modulator was targeted. In fact, inhibition of caspases in general
or specifically of caspase 8 was not efficient in protecting DA
neuronal cultures exposed to MPP+ (Hartmann et al., 2001). In
contrast, Bax-mutant mice were fully protected from the MPTP
intoxication (Vila et al., 2001). Thus, it is conceivable that the
apoptotic pathway might have multiple interactions at different
levels with other cell death processes. In fact, for instance, Bax
can promote mitochondrial fission, which in turn can drive
necroptosis through activation of the dynamin-1-like protein by
PGAM5 (Sheridan et al., 2008; Wang et al., 2012).
Other caspase-independent cell death pathways such as
parthanatos and ferroptosis have been shown to protect from
toxin-induced neuronal degeneration in cells and mice (Vanden
Berghe et al., 2014; Fatokun et al., 2014). Thus, future studies
will be required to elucidate their interactions, redundancies,
and specific inducers for these different cell death modalities.
For instance, experimental evidence suggests that in many
cases, despite suppression of apoptotic pathways, cells
exposed to stresses eventually die by alternative mechanisms
(Hartmann et al., 2001).
Therapies based on inhibiting apoptosis face several chal-
lenges because this process has many pleiotropic functions.
Systemic administration of global anti-apoptotic agents can
likely interfere with physiologic cell death as well as suppression
of tumorigenic processes. In contrast, necroptotic cell death
is exclusively triggered by selected pathological conditions,
and highly selective and potent inhibitors, such as Nec-1s and
others, are effective in blocking this pathway (Degterev and Link-
ermann, 2016), making this strategy more appealing for future
translational applications.
Our study provides a strong case for using iPSC-based
modeling for assessing the consequences of mitochondrial dys-
functions in neural cells and dissecting the initial mechanisms
that lead to neuronal cell loss. This modeling has uncovered nec-
roptosis as a relevant cell death modality whose inhibition might
represent an interesting therapeutic option for counteracting
PD-related neurodegeneration.
EXPERIMENTAL PROCEDURES
Cell Cultures and Neuronal Differentiation
Primary OPA1-mutant fibroblasts derived from PD patients were isolated at
the IRCCS Institute of Neurological Sciences of Bologna. Fibroblasts from
NDs were obtained from the IRCCS Istituto Neurologico C. Besta. iPSC cell
lines weremaintained in feeder-free conditions inmTeSR1 (StemCell Technol-
ogies) and seeded in human embryonic stem cell (HESC)-qualified Matrigel
(Corning)-coated six-well plates.
Molecular Cloning and Viral Infection
The OPA1 coding region followed by an internal ribosome entry site
(IRES)-puromycin resistance cassette was cloned into a lentiviral vector
downstream to the PGK promoter. Replication-incompetent, VSVg-coated
lentiviral particles were packaged in 293T cells. To obtain a stable cell
line with the OPA1 wild-type form, OPA1 mutant and control iPSCs were in-
fected in mTeSR1. Sixteen to 20 hr after infection, cells were switched into
fresh mTeSR media containing puromycin (1 mg/mL, Sigma-Aldrich). After
48 hr, single colonies were picked and seeded in HESC-qualified Matri-
gel-coated six-well plates.
Mitotracker Green and Orange
NPCs from patients and controls were incubated with 50 nM of Mitotracker
Green and Mitotracker Orange (Molecular Probes) for 30 min at 37C, washed
with PBS, and acquired by confocal microscope (Leica TCS SP5, Germany).
For the analysis, the sampleswere acquired on LSR-Fortessa (BD) flow cytom-
eter. All data were analyzed using FCS Ex4press 6 Flow (De Novo Software)
and expressed as mean fluorescence intensity.
LysoTracker Red
NPCs from patients and controls were incubated with 50 nM of LysoTracker
Red (Molecular Probes) for 30 min at 37C, washed with PBS and acquired
by confocal microscope (Leica TCS SP5, Germany). The quantification of
the signal was performed using ImageJ software (NIH, US).
Mitochondrial Morphology
NPCs from patients and controls were dissociated with Accutase and plated
on Matrigel-coated 24-well plates (1 3 40,000 cells per well) in NPC medium.
Mitochondrial morphology was assessed by TOMM20 immunostaining.
Cellular fluorescence images were acquired with a Nikon Eclipse Ni micro-
scope. Imageswere collected using a363/1.4 oil objective and analyzed using
the Mito-Morphology macro in ImageJ.
Animals, Surgery, and Drug Treatment
Nine-week-old male C57BL/6J mice (Charles River Laboratories, France)
underwent cannula implantation to ensure access for subsequent infusion of
drugs. The cannulas (Phymep, France) were placed unilaterally at 0.5 mm
anterior posterior, 1.1 mm lateral, and 2 mm ventral corresponding to the
lateral ventricle. Anterior-posterior and lateral and ventral coordinates are
from bregma and dura mater, respectively. Mice were sorted into three groups
and subjected to distinct treatments. Two groups were intoxicated with
20mg/kgMPTP (i.p.) injected daily for five consecutive days, whereas the third
group received saline. The MPTP groups were alternately microinjected
with Nec-1 (0.2 mg/mL)/Nec-1s (10 mg/kg i.p.) or vehicle (DMSO 1%, methyl-
beta-cyclodextrin 4% in PBS), whereas the saline group received only
Nec-1/Nec-1s. The microinjection was performed by injecting a total volume
of 5 mL at 0.5 mL/min. The treatment with Nec-1/Nec-1s started three days after
the first injection of MPTP and lasted three weeks.
Stereological Counting
The unbiased stereological sampling method was used to quantify dopami-
nergic neurons in substantia nigra pars compacta (SNc). The cell counting
was performed using a Leica DM4000B motorized microscope equipped
with Stereo Investigator (MBF Bioscience, Williston, VT, US). After SNc bound-
aries delimitation, TH-positive (TH+) cells in SNc were on-line counted at
403magnification over five 50 mm-thick sections for each brain and collected
every 200 mm, encompassing the whole SNc. The optical fractionator stereo-
logical probe was then used to estimate the total number of TH+ neurons for
the entire SNc volume.
Statistics
All values are expressed as mean ± SEM. Differences between means were
analyzed using the Student’s t test and one-way or two-way ANOVA depend-
ing on the number of groups and variables in each experiment. In vitro and
in vivo data were then submitted to Tukey or Bonferroni post hoc test using
GraphPad Prism software. The null hypothesis was rejected when p < 0.05.
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